Qiagen Expands NGS Portfolio with Oncology and Immunooncology Panels
The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read MorePosted by Steve Halasey | Dec 20, 2018 | Melanoma, Prostate |
The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read MorePosted by Steve Halasey | Dec 20, 2018 | Prenatal Testing, Research |
The Parsortix system offers the potential to extend NIPT to a wide range of conditions not feasible with existing techniques.
Read MorePosted by Steve Halasey | Dec 20, 2018 | Research |
Study results show that Vectra test results are correlated with treatment response.
Read MorePosted by Steve Halasey | Dec 12, 2018 | Breast, Molecular Diagnostics |
The agency’s approval will permit healthcare professionals to use BRACAnalysis CDx testing to identify patients with HER2-negative metastatic breast cancer who are eligible for treatment with Talzenna.
Read MorePosted by Steve Halasey | Dec 4, 2018 | Software |
ElPrep 4.0 accelerates whole-genome and exome processing pipelines by an order of magnitude, saving a typical lab hundreds of hours of computer processing time.
Read More